Skip to main content
Premium Trial:

Request an Annual Quote

In Silico: Oct 1, 2001

Premium

“People in industry tend to be more aware that they can’t produce open source without getting permission from their company, but academics may not carefully consider intellectual property ownership. In many cases, the university does own the rights to their work.”

— Steve Brenner, assistant professor and leader of a computational genomics research group at UC Berkeley

Find “Legal Pitfalls of Free Bioinformatics Software May Loom Large” by searching: pitfalls

 

Link ’Em Up

The SNP Consortium announced that it had forged agreements with Motorola, Celera, Applied Biosystems, and Rutgers University that would enable it to build a SNP-based linkage map of the human genome by the end of the year. Participants in the deals said that they believed such a map would accelerate the development of new medical treatments and diagnostics.

Find “SNP Consortium Forges Alliances, Announces Plan to Complete SNP Linkage Map by Year’s End” by searching: linkage

 

Size Matters

Researchers at two California-based labs have contested the widely cited size of the human genome, suggesting that the actual number of genes may be greater than 30,000. A comparison of the two published versions of the genome showed that they have only about 16,000 genes in common.

Find “Novartis, Scripps Scientists Challenge Existing Estimate of Genes in Human Genome” by searching: Scripps

 

Bayer Market

Most analysts agree that the future of Bayer’s pharmaceutical group is murky. The drug business was becoming too small to compete in the US drug arena against Goliaths like Pfizer and Bristol-Myers Squibb. But a merger that results in a change in ownership of the division might also impact the dozen or so deals Bayer has with bioinformatics and genomics companies.

Find “Will Bayer’s Woes Intensify its Current Bioinformatics and Genomics Deals?” by searching: Baycol

 

Where’s the Pharma?

“The effort shouldn’t be driven by the hardware vendors. It should be driven by the end-users. A big piece that I see lacking is that pharma isn’t visible at all.” — Lionel Binns, worldwide life and materials science group manager for high-performance technical computing at Compaq

Find “Following Initial Success, I3C Faces a New Round of Challenges as Participation Grows” by searching: I3C

 

Boost for Accelrys?

Pharmacopeia and Eos Biotechnology announced plans for a merger, which could boost Pharmacopeia’s slumping discovery revenues but also stands to benefit its Accelrys software unit. One option would be an IPO for Accelrys, but that decision will be made at least a year after its June 2001 launch.

Find “With Eos Merger, Pharmacopeia’s Drug Discovery Gain Also Helps Accelrys” by searching: Eos

 

Beyond Bias

How can researchers amplify minute volumes of RNA to produce enough aRNA for an array without getting an amplification bias? Until now, the only commonly available solution has been the Eberwine T7 protocol, which is tough to fine-tune. Arcturus has recently introduced a commercial alternative called RiboAmp. Will it really be the answer? The proof will lie in the product of the amplification.

Find “RNA Amplification Using T7 Method Gains Popularity as Commercial Version is Introduced” by searching: T7

 

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.